Ciprofloxacin Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
Therapeutic Class
Antimicrobial
Subclass
Fluoroquinolone
Speciality
Infectious Disease
Schedule (India)
Schedule H
Routes
Oral, Intravenous, Ophthalmic, Otic
Formulations
| Form | Strengths |
|---|---|
| Film-coated Tablets | 250 mg; 500 mg; 750 mg |
| Extended-release Tablets | 500 mg; 1000 mg |
| Oral Suspension | 250 mg per 5 mL (limited availability) |
| IV Infusion | 100 mg/50 mL; 200 mg/100 mL; 400 mg/200 mL |
| Eye Drops | 0.3% w/v (5 mL, 10 mL) |
| Ear Drops | 0.3% w/v (5 mL, 10 mL) |
| Eye Ointment | 0.3% w/w |
| Form | Strengths |
|---|---|
| Film-coated Tablets | 250 mg; 500 mg; 750 mg |
| Extended-release Tablets | 500 mg; 1000 mg |
| Oral Suspension | 250 mg per 5 mL (limited availability) |
| IV Infusion | 100 mg/50 mL; 200 mg/100 mL; 400 mg/200 mL |
| Eye Drops | 0.3% w/v (5 mL, 10 mL) |
| Ear Drops | 0.3% w/v (5 mL, 10 mL) |
| Eye Ointment | 0.3% w/w |
Unidentified
Adult indications
INDICATIONS + DOSING ā FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
1. Uncomplicated Urinary Tract Infection (Acute Cystitis)
Adults:
| Parameter | Recommendation |
|---|---|
| Starting dose | 250 mg orally every 12 hours |
| Titration | Not applicable |
| Usual maintenance dose | 250ā500 mg orally every 12 hours |
| Maximum dose | 500 mg every 12 hours |
| Duration | 3 days (women); 7 days (men) |
Clinical Note: NOT first-line for uncomplicated UTI due to high resistance rates in India. Reserve for culture-confirmed susceptible organisms or when first-line agents (nitrofurantoin, fosfomycin) are contraindicated or have failed.
2. Complicated Urinary Tract Infection / Pyelonephritis
Adults ā Oral:
| Parameter | Recommendation |
|---|---|
| Starting dose | 500 mg orally every 12 hours |
| Titration | Increase to 750 mg every 12 hours for severe infections |
| Usual maintenance dose | 500ā750 mg orally every 12 hours |
| Maximum dose | 750 mg every 12 hours |
| Duration | 7ā14 days |
Adults ā Intravenous (Severe/Hospitalised):
| Parameter | Recommendation |
|---|---|
| Starting dose | 400 mg IV every 12 hours |
| Titration | May increase frequency to every 8 hours for severe infections |
| Usual maintenance dose | 400 mg IV every 8ā12 hours |
| Maximum dose | 400 mg IV every 8 hours (1200 mg/day) |
| Duration | 7ā14 days; step-down to oral when clinically stable |
3. Enteric Fever (Typhoid/Paratyphoid) ā Only If Susceptible
Adults:
| Parameter | Recommendation |
|---|---|
| Starting dose | 500 mg orally every 12 hours |
| Titration | May increase to 750 mg every 12 hours for severe cases |
| Usual maintenance dose | 500ā750 mg orally every 12 hours |
| Maximum dose | 750 mg every 12 hours |
| Duration | 7ā10 days (uncomplicated); 10ā14 days (complicated) |
Clinical Note: High fluoroquinolone resistance (>80% in many regions of India) limits empiric use. Use ONLY when culture and sensitivity confirms susceptibility. Azithromycin or ceftriaxone preferred for empiric therapy per ICMR guidelines.
4. Acute Bacterial Diarrhoea (Invasive ā Shigella, Salmonella, Campylobacter)
Adults:
| Parameter | Recommendation |
|---|---|
| Starting dose | 500 mg orally every 12 hours |
| Titration | Not applicable |
| Usual maintenance dose | 500 mg every 12 hours |
| Maximum dose | 500 mg every 12 hours |
| Duration | 3ā5 days |
Clinical Note: Reserve for moderate-severe invasive diarrhoea with systemic features. Azithromycin increasingly preferred due to quinolone resistance in enteric pathogens.
5. Skin and Soft Tissue Infections (Gram-Negative Susceptible Organisms)
Adults ā Oral:
| Parameter | Recommendation |
|---|---|
| Starting dose | 500 mg orally every 12 hours |
| Titration | Increase to 750 mg every 12 hours for severe infections |
| Usual maintenance dose | 500ā750 mg orally every 12 hours |
| Maximum dose | 750 mg every 12 hours |
| Duration | 7ā14 days |
Adults ā Intravenous:
| Parameter | Recommendation |
|---|---|
| Starting dose | 400 mg IV every 12 hours |
| Titration | Increase to every 8 hours for severe/complicated infections |
| Usual maintenance dose | 400 mg IV every 8ā12 hours |
| Maximum dose | 400 mg IV every 8 hours |
| Duration | 7ā14 days |
Clinical Note: Not effective against MRSA or streptococci. Use only when gram-negative susceptible organisms confirmed or strongly suspected (e.g., diabetic foot with Pseudomonas risk).
6. Hospital-Acquired Pneumonia / Ventilator-Associated Pneumonia (Including Pseudomonas Coverage)
Adults:
| Parameter | Recommendation |
|---|---|
| Starting dose | 400 mg IV every 8 hours |
| Titration | Not applicable |
| Usual maintenance dose | 400 mg IV every 8 hours |
| Maximum dose | 400 mg IV every 8 hours (1200 mg/day) |
| Duration | 7ā14 days based on clinical response |
Clinical Note: Usually combined with anti-pseudomonal beta-lactam for HAP/VAP. Monotherapy not recommended for critically ill patients.
7. Intra-Abdominal Infections (In Combination with Metronidazole)
Adults:
| Parameter | Recommendation |
|---|---|
| Starting dose | 400 mg IV every 12 hours (with metronidazole) |
| Titration | May increase to every 8 hours for severe infections |
| Usual maintenance dose | 400 mg IV every 8ā12 hours |
| Maximum dose | 400 mg IV every 8 hours |
| Duration | 4ā7 days with adequate source control |
8. Bacterial Conjunctivitis (Ophthalmic)
Adults and Children:
| Parameter | Recommendation |
|---|---|
| Starting dose | 1ā2 drops into affected eye(s) every 2 hours while awake |
| Titration | Reduce frequency as infection improves |
| Usual maintenance dose | 1ā2 drops every 4ā6 hours |
| Maximum dose | 2 drops every 2 hours (first 2 days) |
| Duration | 7 days |
9. Acute Otitis Externa / Chronic Suppurative Otitis Media (Otic)
Adults and Children:
| Parameter | Recommendation |
|---|---|
| Starting dose | 3ā4 drops into affected ear(s) twice daily |
| Titration | Not applicable |
| Usual maintenance dose | 3ā4 drops twice daily |
| Maximum dose | 4 drops three times daily |
| Duration | 7ā14 days |
Secondary Indications ā Adults (Off-label, if any)
| Indication | Dose | Duration | Notes |
|---|---|---|---|
| Chronic Bacterial Prostatitis | 500ā750 mg orally every 12 hours | 4ā6 weeks | OFF-LABEL. Specialist only. One of few agents with good prostatic penetration. Culture-confirmed susceptibility required |
| Bone and Joint Infections (Osteomyelitis, Septic Arthritis) | 750 mg orally every 12 hours OR 400 mg IV every 8ā12 hours | 6ā12 weeks (osteomyelitis) | OFF-LABEL. Specialist only. Usually in combination with other agents (e.g., rifampicin for staphylococcal prosthetic joint infection). Based on orthopaedic infectious disease protocols |
| Post-Exposure Prophylaxis ā Anthrax (Bioterrorism) | 500 mg orally every 12 hours | 60 days | OFF-LABEL. Public health emergency use. Per NCDC/ICMR guidelines |
| Neutropenic Fever (Low-Risk, Outpatient) | 500ā750 mg orally every 12 hours (with amoxicillin-clavulanate) | Until neutrophil recovery | OFF-LABEL. Specialist only. Based on oncology protocols for low-risk febrile neutropenia |
Paediatric indications
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
General Principle: Ciprofloxacin is NOT routinely recommended in children <18 years due to risk of cartilage toxicity (arthropathy). Use ONLY when no suitable alternative exists and benefits outweigh risks. Requires specialist supervision.
1. Enteric Fever (MDR Typhoid) ā Culture-Confirmed Susceptibility
Children ≥1 year:
| Parameter | Recommendation |
|---|---|
| Starting dose | 10ā15 mg/kg orally every 12 hours |
| Titration | Not applicable |
| Usual maintenance dose | 10ā15 mg/kg every 12 hours |
| Maximum single dose | 500 mg |
| Maximum daily dose | 1000 mg |
| Duration | 7ā10 days |
Clinical Note: Use only for culture-confirmed fluoroquinolone-susceptible strains when ceftriaxone/azithromycin not suitable.
2. Complicated Urinary Tract Infection / Pyelonephritis
Children ≥1 year:
| Parameter | Recommendation |
|---|---|
| Starting dose | 10 mg/kg orally/IV every 12 hours |
| Titration | Not applicable |
| Usual maintenance dose | 10ā15 mg/kg every 12 hours |
| Maximum single dose (Oral) | 500 mg |
| Maximum single dose (IV) | 400 mg |
| Duration | 7ā14 days |
3. Pseudomonal Infections (Cystic Fibrosis, Immunocompromised)
Children ≥1 year:
| Parameter | Recommendation |
|---|---|
| Starting dose | 15 mg/kg orally/IV every 12 hours |
| Titration | May increase to 20 mg/kg every 12 hours for severe infections |
| Usual maintenance dose | 15ā20 mg/kg every 12 hours |
| Maximum single dose (Oral) | 750 mg |
| Maximum single dose (IV) | 400 mg |
| Duration | As per indication and specialist guidance |
4. Ophthalmic Infections (Bacterial Conjunctivitis, Corneal Ulcer)
All ages (including neonates for topical use):
| Parameter | Recommendation |
|---|---|
| Starting dose | 1ā2 drops every 2 hours while awake |
| Titration | Reduce frequency as infection improves |
| Usual maintenance dose | 1ā2 drops every 4ā6 hours |
| Duration | 7ā14 days |
5. Otitis Externa / Chronic Suppurative Otitis Media
Children ≥1 year:
| Parameter | Recommendation |
|---|---|
| Starting dose | 3 drops into affected ear twice daily |
| Usual maintenance dose | 3 drops twice daily |
| Duration | 7ā14 days |
Secondary Indications ā Paediatrics (Off-label, if any)
| Indication | Dose | Duration | Notes |
|---|---|---|---|
| Febrile Neutropenia (when IV not feasible) | 10ā15 mg/kg orally every 12 hours (max 500 mg/dose) | Until neutrophil recovery | OFF-LABEL. Specialist oncology supervision only. In combination with amoxicillin-clavulanate for outpatient low-risk neutropenia |
Age Restrictions and Safety Monitoring
| Age Group | Recommendation |
|---|---|
| <1 year | Avoid systemic use; topical ophthalmic/otic may be used with caution |
| 1ā18 years | Systemic use only when no alternative exists; specialist supervision mandatory |
| >18 years | Adult dosing applicable |
Safety Monitoring in Paediatrics:
- Monitor for musculoskeletal symptoms (joint pain, swelling, tendon pain) ā discontinue if occurs
- Baseline and periodic assessment of joints in prolonged therapy
- LFTs if treatment >7 days
- CNS symptoms (headache, confusion, seizures)
Renal Adjustments
Dose adjustment required based on creatinine clearance:
| CrCl (mL/min) | Oral Dosing | IV Dosing |
|---|---|---|
| >50 | No adjustment | No adjustment |
| 30ā50 | 250ā500 mg every 12 hours | 200ā400 mg every 12 hours |
| 10ā29 | 250ā500 mg every 18ā24 hours | 200ā400 mg every 18ā24 hours |
| <10 | 250ā500 mg every 24 hours | 200ā400 mg every 24 hours |
| Haemodialysis | 250ā500 mg every 24 hours (dose after dialysis on dialysis days) | 200ā400 mg every 24 hours (dose after dialysis) |
| CAPD | 250ā500 mg every 24 hours | 200ā400 mg every 24 hours |
| CRRT | 200ā400 mg every 12 hours (adjust per effluent rate) | As per clinical response |
Hepatic adjustment
Contraindications
- Known hypersensitivity to ciprofloxacin or any fluoroquinolone antibiotic
- Concurrent use with tizanidine ā risk of severe hypotension and excessive sedation (pharmacokinetic interaction via CYP1A2 inhibition)
- History of tendon disorder related to fluoroquinolone use (tendinitis, tendon rupture)
- Myasthenia gravis ā risk of severe exacerbation including respiratory failure
Cautions
- History of epilepsy or conditions predisposing to seizures ā lowers seizure threshold
- Pre-existing QT prolongation or concurrent use of QT-prolonging drugs
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency ā haemolytic reactions reported
- Diabetes mellitus ā risk of severe hypoglycaemia or hyperglycaemia
- Elderly patients ā increased risk of tendon rupture, QT prolongation, and CNS effects
- Concurrent corticosteroid use ā significantly increased tendon rupture risk
- Renal impairment ā requires dose adjustment
- History of peripheral neuropathy
- Aortic aneurysm or dissection risk factors ā emerging data on association with aortic events
Pregnancy
| Parameter | Recommendation |
|---|---|
| Overall safety | Generally AVOID; potential risk of fetal cartilage damage based on animal studies |
| Risk category | Category C (US legacy); Not recommended in pregnancy per Indian practice |
| Preferred alternatives | Cephalosporins (ceftriaxone, cefixime), nitrofurantoin (for UTI ā avoid near term), azithromycin (for typhoid) |
| When it may be used | Only when no safer alternative available and maternal benefit clearly outweighs fetal risk; specialist decision |
| Monitoring | Fetal growth; maternal adverse reactions; avoid in first trimester if possible |
Lactation
| Parameter | Recommendation |
|---|---|
| Compatibility | Use with caution; excreted in breast milk |
| Drug levels in milk | Low to moderate; infant receives small amounts |
| Preferred alternatives | Amoxicillin, cephalosporins, azithromycin |
| Infant monitoring | Observe for diarrhoea, oral thrush, feeding difficulties; theoretical concern for cartilage effects (not proven in humans) |
Note: If ciprofloxacin essential, consider temporary interruption of breastfeeding during treatment course.
Elderly
| Parameter | Recommendation |
|---|---|
| Starting dose | Lower end of dosing range (250ā500 mg orally or 200ā400 mg IV every 12 hours) |
| Titration | Cautious; assess renal function before escalating |
| Renal consideration | Age-related decline in renal function common; calculate CrCl and adjust dose accordingly |
| Specific risks | Significantly increased risk of: Achilles tendon rupture (especially with concurrent steroids); QT prolongation and arrhythmias; CNS effects (confusion, hallucinations, delirium); hypoglycaemia (especially in diabetics on sulfonylureas/insulin) |
| Monitoring | ECG if cardiac risk factors; blood glucose in diabetics; tendon symptoms; mental status |
Major drug interactions
| Drug | Interaction | Recommendation |
|---|---|---|
| Tizanidine | CYP1A2 inhibition by ciprofloxacin causes 10-fold increase in tizanidine levels → severe hypotension, excessive sedation | CONTRAINDICATED ā do not co-administer |
| Theophylline/Aminophylline | CYP1A2 inhibition → increased theophylline levels → toxicity (seizures, arrhythmias, nausea) | Reduce theophylline dose by 30ā40%; monitor levels closely |
| QT-prolonging drugs (Amiodarone, Sotalol, Haloperidol, Ondansetron, Erythromycin) | Additive QT prolongation → risk of torsades de pointes | Avoid combination if possible; if essential, baseline and follow-up ECG; correct electrolytes |
| Warfarin/Acenocoumarol | Enhanced anticoagulant effect via CYP1A2 inhibition and gut flora alteration | Monitor INR closely (within 3ā5 days of starting ciprofloxacin); adjust anticoagulant dose |
| Methotrexate | Reduced renal clearance of methotrexate → increased toxicity | Monitor for methotrexate toxicity; consider dose reduction or avoid combination |
| Duloxetine | CYP1A2 inhibition → increased duloxetine levels → serotonin syndrome risk | Avoid combination; if essential, use lowest duloxetine dose and monitor |
| Phenytoin | Altered phenytoin levels (increased or decreased) | Monitor phenytoin levels; adjust dose as needed |
Moderate drug interactions
| Drug | Interaction | Recommendation |
|---|---|---|
| Antacids (Aluminium/Magnesium hydroxide), Iron, Calcium, Zinc, Sucralfate | Form chelation complexes → significantly reduced ciprofloxacin absorption | Administer ciprofloxacin 2 hours before or 6 hours after these products |
| Dairy products / Calcium-fortified foods | Reduced absorption (less than antacids but still significant) | Avoid taking ciprofloxacin with dairy; may take with food otherwise |
| Sulfonylureas (Glibenclamide, Glimepiride) / Insulin | Risk of severe hypoglycaemia or hyperglycaemia | Monitor blood glucose closely; counsel patient about symptoms |
| Cyclosporine | Increased cyclosporine nephrotoxicity; ciprofloxacin levels may also increase | Monitor renal function and cyclosporine levels |
| NSAIDs | Potential increased risk of CNS stimulation and seizures | Use with caution, especially in patients with seizure history |
| Rifampicin | May reduce ciprofloxacin levels via enhanced metabolism | Monitor clinical efficacy; consider ciprofloxacin dose increase |
| Clozapine | CYP1A2 inhibition → increased clozapine levels → toxicity | Monitor clozapine levels and for adverse effects; dose reduction may be needed |
| Probenecid | Reduced renal clearance of ciprofloxacin → increased levels | Monitor for ciprofloxacin toxicity |
Common Adverse effects'
- Nausea and vomiting
- Diarrhoea
- Abdominal pain/discomfort
- Headache
- Dizziness
- Rash and pruritus
- Photosensitivity
- Transient elevation of liver enzymes
- Insomnia
- Injection site reactions (IV use)
Serious Adverse effects
| Adverse Effect | Clinical Notes |
|---|---|
| Tendinitis / Tendon rupture | Most commonly Achilles tendon; risk highest in elderly, those on corticosteroids, and renal transplant recipients. Discontinue immediately if tendon pain occurs; avoid exercise |
| QT prolongation / Torsades de pointes | Risk increased with electrolyte disturbances, concurrent QT-prolonging drugs, cardiac disease. ECG monitoring recommended in at-risk patients |
| Severe hypoglycaemia / Hyperglycaemia | Can be life-threatening; more common in diabetics on glucose-lowering therapy. Discontinue if severe dysglycaemia occurs |
| CNS toxicity (Seizures, Toxic psychosis, Hallucinations, Encephalopathy) | Risk increased in elderly, those with CNS disorders, renal impairment. Discontinue immediately |
| Peripheral neuropathy | May be irreversible; presents as pain, burning, tingling, numbness. Discontinue at first symptoms |
| Clostridioides difficile-associated diarrhoea (CDAD) | May occur during or after therapy. Discontinue and treat appropriately if confirmed |
| Anaphylaxis / Severe allergic reactions | Discontinue immediately; manage with adrenaline and supportive care |
| Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis | Very rare; discontinue immediately; hospitalisation required |
| Hepatotoxicity (including fulminant hepatic failure) | Rare; discontinue if jaundice or significant LFT elevation |
| Aortic aneurysm / Dissection | Emerging association; use with caution in patients with risk factors (Marfan syndrome, elderly, hypertension) |
| Exacerbation of myasthenia gravis | May cause life-threatening respiratory failure |
Monitoring requirements
| Phase | Parameters |
|---|---|
| Baseline | Serum creatinine/eGFR, LFTs, blood glucose (diabetics), ECG (if cardiac risk factors or concurrent QT-prolonging drugs), allergy history |
| During treatment | Clinical response; tendon symptoms (pain, swelling ā counsel patient to report); CNS symptoms; blood glucose in diabetics; signs of C. difficile infection |
| Prolonged therapy (>7ā14 days) | LFTs weekly; renal function; CBC if indicated; reassess clinical need for continuation |
| High-risk patients | ECG monitoring for QT; enhanced glucose monitoring |
Brands in India
| Ciplox | Cipla | Tablets, IV, Eye/Ear drops |
|---|---|---|
| Cifran | Sun Pharma | Tablets, IV |
| Ciprobid | Zydus | Tablets |
| Quintor | Torrent | Tablets |
| Zoxan | FDC | Tablets |
| Alcipro | Alkem | Tablets, IV |
| Ciprofloxacin (Generic) | Multiple | All forms |
Fixed-Dose Combinations (Note: Use rational combinations only):
- Cifran-OZ, Ciplox-TZ (Ciprofloxacin + Tinidazole) ā for mixed aerobic-anaerobic infections
- Ciplox-D (Ciprofloxacin + Dexamethasone eye/ear drops) ā for inflammatory infections
Price range (INR)
| Formulation | Approximate Price |
|---|---|
| Tablet 250 mg (per tablet) | ā¹2āā¹5 |
| Tablet 500 mg (per tablet) | ā¹3āā¹8 |
| Tablet 750 mg (per tablet) | ā¹8āā¹15 |
| IV 200 mg/100 mL | ā¹25āā¹60 |
| IV 400 mg/200 mL | ā¹40āā¹90 |
| Eye drops 0.3% (5 mL) | ā¹15āā¹40 |
| Ear drops 0.3% (5 mL) | ā¹15āā¹40 |
Regulatory Note: Listed under NLEM 2022 (select formulations). NPPA price-controlled. Available through government supply at lower rates.
Clinical pearls'
- Resistance is the major issue: Fluoroquinolone resistance in enteric pathogens exceeds 80% in many parts of India. NEVER use empirically for typhoid ā always obtain culture/sensitivity. Azithromycin or ceftriaxone preferred for empiric enteric fever treatment.
- Dairy and antacid timing: Ciprofloxacin absorption significantly reduced by dairy, antacids, iron, and calcium supplements. Administer 2 hours before or 6 hours after these products to ensure therapeutic levels.
- Tendon rupture warning: Educate all patients, especially elderly and those on corticosteroids, to immediately stop ciprofloxacin and rest the affected limb if tendon pain occurs. Risk persists for months after stopping the drug.
- QT risk assessment: Before prescribing, check for concurrent QT-prolonging medications (common in India: azithromycin, ondansetron, antipsychotics). Consider baseline ECG in elderly or those with cardiac history.
- Diabetic caution: Both severe hypoglycaemia and hyperglycaemia reported. Counsel diabetic patients on sulfonylureas or insulin to monitor glucose closely and recognise warning symptoms.
- Not for routine use in children: Systemic ciprofloxacin in children should be an exception, not routine. Document indication and lack of alternatives. Topical ophthalmic/otic use is generally safe.
Version
RxIndia v1.0 ā 03 May 2025
Reference
-
- CDSCO Drug Database and Product Inserts
- Indian Pharmacopoeia 2022
- National List of Essential Medicines (NLEM) 2022
- API Textbook of Medicine (11th Edition)
- ICMR Antimicrobial Resistance Surveillance Network Reports
- ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes
- AIIMS Antimicrobial Policy and Treatment Guidelines
- NCDC Typhoid and Enteric Fever Treatment Modules
- IAP Textbook of Paediatric Infectious Diseases
- Goodman & Gilman's The Pharmacological Basis of Therapeutics
- Harrison's Principles of Internal Medicine (21st Edition)
āļø
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.